


## Sirt1/2-IN-2

Cat. No.:	HY-155727
CAS No.:	670267-73-9
Molecular Formula:	C <sub>18</sub> H <sub>14</sub> N <sub>4</sub> O <sub>3</sub> S <sub>2</sub>
Molecular Weight:	398.46
Target:	Sirtuin; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Sirt1/2-IN-2 (compound hsa55) is a dual inhibitor of SIRT1/2 with IC <sub>50</sub> s of 1.8 μM (SIRT1) and 2.4 μM (SIRT2), respectively. Sirt1/2-IN-2 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-2 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 1.8 μM (SIRT1), 2.4 μM (SIRT2), 65 μM (SIRT3) <sup>[1]</sup>
<b>In Vitro</b>	Sirt1/2-IN-2 (compound hsa55) (5 μM; 48 h) induces apoptosis in different tumor cells, with IC <sub>50</sub> s of 13 μM (MV4-11), 11.5 μM (MOLM-13), 34.4 μM (THP1), 27.5 μM (Jurkat), respectively <sup>[1]</sup> . Sirt1/2-IN-2 (100 μM; 30 min) decreases the thermal stability of both SIRT1 and SIRT2 proteins at different temperatures, and also (25 μM, 30 μM; 24 h) increase level of the acetylated form of p53 and α-tubulin in MOLM-13 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Cai H, et al. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. J Chem Inf Model. 2023 Aug 14;63(15):4780-4790.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA